But with Novartis failing to convince European regulators about the merits of Xiidra last year, and Allergan's ageing Restasis potentially facing generic competition, there’s a lot to play for ...

Lying in wait at the moment are well-entrenched therapies like Novartis' Xiidra (lifitegrast) and AbbVie's Restasis (cyclosporine), which are not considered to be particularly effective and have ...

Thank you for reporting this station. We will review the data in question. You are about to report this weather station for bad data. Please select the information that is incorrect.

Planet or Plastic? is National Geographic’s multiyear effort to raise awareness about the global plastic trash crisis. Come to this page often to learn more, and find out what you can do to ...

Thank you for reporting this station. We will review the data in question. You are about to report this weather station for bad data. Please select the information that is incorrect.

Tim Harford explains - and sometimes debunks - the numbers and statistics used in political debate, the news and everyday life ...

Since assuming the CEO post in 2015, Weber has guided Takeda through a number of critical business developments. Key among these were the acquisition of Shire for $62 billion as well as the sale of ...

DelveInsight's analysis indicates a promising outlook for the dry eye disease market from 2024 to 2034, with positive growth anticipated. This growth trajectory is attributed to the emergence ...